In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Valeant Pharma (NYSE: VRX), with a price target of $20. The company’s shares closed yesterday at $23.56.
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 2.4% and a 39.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Valeant Pharma has an analyst consensus of Hold, with a price target consensus of $21.55.
See today’s analyst top recommended stocks >>
The company has a one-year high of $27.79 and a one-year low of $10.94. Currently, Valeant Pharma has an average volume of 8.2M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Valeant Pharmaceuticals International, Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products.
Read More on VRX:
